Stocks and Investing Stocks and Investing
Tue, June 11, 2024

Serge Belanger Reiterated (VRDN) at Strong Buy and Held Target at $30 on, Jun 11th, 2024


Published on 2024-10-28 11:52:51 - WOPRAI, Serge Belanger
  Print publication without navigation


Serge Belanger of Needham, Reiterated "Viridian Therapeutics, Inc." (VRDN) at Strong Buy and Held Target at $30 on, Jun 11th, 2024.

Serge has made no other calls on VRDN in the last 4 months.



There are 6 other peers that have a rating on VRDN. Out of the 6 peers that are also analyzing VRDN, 2 agree with Serge's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Kalpit Patel of "B. Riley Securities" Downgraded from Strong Buy to Hold and Decreased Target to $20 on, Thursday, May 9th, 2024
  • Michael Higgins of "Ladenburg Thalmann" Downgraded from Strong Buy to Hold on, Thursday, May 9th, 2024


These are the ratings of the 4 analyists that currently disagree with Serge


  • Richard Law of "Goldman Sachs" Initiated at Strong Buy and Held Target at $23 on, Thursday, June 6th, 2024
  • Douglas Tsao of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $27 on, Thursday, May 9th, 2024
  • Leland Gershell of "Oppenheimer" Maintained at Buy with Decreased Target to $31 on, Thursday, May 9th, 2024
  • Laura Chico of "Wedbush" Maintained at Buy with Increased Target to $40 on, Wednesday, February 28th, 2024
Contributing Sources